Breye Therapeutics Raises $73M to Revolutionize Eye Disease Treatment

Jan de Vries · 2026-10-02

Imagine a world where treating a serious eye disease doesn't require a needle in your eye. That's the future Breye Therapeutics is working toward. This Danish biopharma company just raised a whopping $73 million (€67.5 million) to push forward an oral therapy that could change everything for people with retinal diseases. ### The Big Raise Breye closed an oversubscribed Series A round, co-led by Mission BioCapital and Novo Holdings, with participation from Sound Bioventures and several new investors. This influx of cash will help advance their lead candidate, danegaptide, into the next phase of clinical trials. It's a huge vote of confidence for a company that only emerged from stealth in 2022. ### Why Danegaptide Matters Danegaptide is a first-in-class oral small molecule that stabilizes retinal blood vessels. It's designed to treat diabetic retinopathy, a condition that affects about 130 million people worldwide. Current treatments involve injections directly into the eye, which are uncomfortable and often lead to poor adherence. Danegaptide could offer a patient-friendly alternative. > "This financing enables us to advance danegaptide, our pioneering, first-in-class oral treatment for diabetic retinopathy, to the next stage of clinical development – bringing a much-needed patient-friendly treatment option closer to those living with this debilitating eye disease." – Ulrik Mouritzen, CEO of Breye Therapeutics ### Promising Early Results Last year, Breye completed a Phase 1b trial in patients with non-proliferative diabetic retinopathy (NPDR). The results showed that danegaptide was well-tolerated across all doses and even hinted at clinical activity, with retinal imaging suggesting reduced vascular leakage. That's a big deal because leakage is a core problem in NPDR. ### A Growing Market Diabetic retinopathy therapeutics is already a massive market, valued at nearly $10 billion. And it's expected to nearly double in the next decade, with a compound annual growth rate of 6.5%. With limited options for early-stage patients, danegaptide could capture a significant share. ### What's Next? Breye plans to use the funds to move danegaptide into later-stage trials. They're also developing oral therapies for other eye diseases like age-related macular degeneration and glaucoma. If successful, they could transform how we treat retinal diseases, making it as easy as taking a pill. - **Oral delivery**: No more eye injections. - **First-in-class**: A novel mechanism of action. - **Broad potential**: Could treat multiple eye conditions. This funding round is a clear signal that investors believe in Breye's approach. And for patients, it offers hope for a simpler, more tolerable treatment. Keep an eye on this company – they might just change the way we see eye disease.